Drusolv Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Series A
  • (In Progress)

  • Latest Deal Amount
  • $60M

  • Investors
  • 3

Drusolv Therapeutics General Information

Description

Operator of a clinical-stage drug company intended to develop a high-dose oral statin for early intervention in age-related macular degeneration (AMD). The company's product is aimed at patients who are still in the intermediate stage of the disease and currently have minimal options to prevent progression to late-stage blindness, enabling doctors to treat patients and substantially reduce progression to late-stage blindness.

Contact Information

Website
www.drusolv.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1425 Locust Street
  • Unit 7C
  • Philadelphia, PA 19102
  • United States
+1 (404)
Primary Industry
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • 1425 Locust Street
  • Unit 7C
  • Philadelphia, PA 19102
  • United States
+1 (404)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Drusolv Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A) 01-Jan-2024 $60M In Progress Clinical Trials - Phase 3
2. Secondary Transaction - Private Completed Clinical Trials - Phase 2
1. Seed Round 12-Apr-2022 $2M $2M Completed Clinical Trials - Phase 2
To view Drusolv Therapeutics’s complete valuation and funding history, request access »

Drusolv Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Drusolv Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Axilium Holding Venture Capital Minority
BrightFocus Foundation Corporation Minority
Texas Halo Fund Venture Capital Minority
To view Drusolv Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial

Drusolv Therapeutics FAQs

  • When was Drusolv Therapeutics founded?

    Drusolv Therapeutics was founded in 2017.

  • Where is Drusolv Therapeutics headquartered?

    Drusolv Therapeutics is headquartered in Philadelphia, PA.

  • What is the size of Drusolv Therapeutics?

    Drusolv Therapeutics has 3 total employees.

  • What industry is Drusolv Therapeutics in?

    Drusolv Therapeutics’s primary industry is Drug Discovery.

  • Is Drusolv Therapeutics a private or public company?

    Drusolv Therapeutics is a Private company.

  • What is the current valuation of Drusolv Therapeutics?

    The current valuation of Drusolv Therapeutics is .

  • What is Drusolv Therapeutics’s current revenue?

    The current revenue for Drusolv Therapeutics is .

  • How much funding has Drusolv Therapeutics raised over time?

    Drusolv Therapeutics has raised $2M.

  • Who are Drusolv Therapeutics’s investors?

    Axilium Holding, BrightFocus Foundation, and Texas Halo Fund have invested in Drusolv Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process